A detailed history of Jpmorgan Chase & CO transactions in Clear Point Neuro, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 9,770 shares of CLPT stock, worth $114,015. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,770
Previous 6,158 58.66%
Holding current value
$114,015
Previous $33,000 230.3%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$5.3 - $13.18 $19,143 - $47,606
3,612 Added 58.66%
9,770 $109,000
Q2 2024

Aug 12, 2024

SELL
$5.25 - $6.73 $50,893 - $65,240
-9,694 Reduced 61.15%
6,158 $33,000
Q1 2024

May 10, 2024

SELL
$6.03 - $7.86 $93,887 - $122,380
-15,570 Reduced 49.55%
15,852 $107,000
Q4 2023

Feb 12, 2024

SELL
$4.46 - $7.07 $46,303 - $73,400
-10,382 Reduced 24.83%
31,422 $213,000
Q3 2023

Nov 14, 2023

SELL
$5.01 - $7.09 $43,937 - $62,179
-8,770 Reduced 17.34%
41,804 $209,000
Q2 2023

Aug 11, 2023

BUY
$6.54 - $10.58 $93,888 - $151,886
14,356 Added 39.64%
50,574 $366,000
Q1 2023

May 11, 2023

BUY
$7.33 - $10.63 $12,600 - $18,272
1,719 Added 4.98%
36,218 $305,000
Q4 2022

Feb 13, 2023

BUY
$7.7 - $11.21 $13,036 - $18,978
1,693 Added 5.16%
34,499 $292,000
Q3 2022

Nov 14, 2022

SELL
$9.82 - $16.49 $6,854 - $11,510
-698 Reduced 2.08%
32,806 $340,000
Q2 2022

Aug 11, 2022

SELL
$7.09 - $13.65 $169,131 - $325,620
-23,855 Reduced 41.59%
33,504 $437,000
Q1 2022

May 11, 2022

BUY
$7.8 - $11.6 $36,862 - $54,821
4,726 Added 8.98%
57,359 $597,000
Q4 2021

Feb 10, 2022

BUY
$11.08 - $18.86 $15,656 - $26,649
1,413 Added 2.76%
52,633 $590,000
Q3 2021

Nov 12, 2021

BUY
$16.58 - $22.25 $849,227 - $1.14 Million
51,220 New
51,220 $910,000

Others Institutions Holding CLPT

About ClearPoint Neuro, Inc.


  • Ticker CLPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 24,488,300
  • Market Cap $286M
  • Description
  • ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain ...
More about CLPT
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.